HeraMED has received its first investment from a leading impact fund. Pic: Getty Images.
Health & Biotech
Special Report: HeraMED has received a boost in its efforts to lead the transformation of maternity care globally, accepting a $1.02m private placement from three prominent institutional investors to advance its commercial growth strategy.
HeraMED (ASX:HMD) said the placement included its first investment from a leading impact fund, validating the medical data and technology company’s commitment to deliver positive social impact in the healthcare sector.
Under the placement HMD will raise $1.02m through the issue of 60 million new ordinary shares at 1.7 cents/share in a private placement.
The issue price represents a 19% discount to the 15-day VWAP of 2.1 cents, based on the last closing price on November 8, 2024, and is subject to shareholder approval at an upcoming EGM.
The terms are the same as a recent capital raise announced in October, where HMD raised $3.1m in a two-tranche private placement to sophisticated and professional investors.
HMD aims to redefine how prenatal and postnatal care is delivered and experienced with its medical grade, clinically validated, end-to-end digital remote monitoring and maternity care platform HeraCARE.
The platform enables healthcare providers to monitor their maternity patients remotely with personalised care plans via a mobile app and a smart kit of connected devices including the company’s clinically validated, foetal and maternal heart rate monitor HeraBEAT.
Read more on this here > HeraMED revolutionising maternity care with digital technology
HMD said the placement funds further strengthen its financial position and enable its commercialisation strategy for HeraCARE.
The company noted it would continue to expand its research collaborations and develop new evidence-based care models to improve pregnancy outcomes across diverse communities.
HMD is also working to build a sustainable pipeline of non-dilutive funding through grants and research partnerships.
In 2024, HMD said the number and value of grants connected to remote maternity care significantly increased in Australia, the US, and Europe.
To ensure HMD successfully applied for and had the best chance of winning these grants, the company said it needed to invest in dedicated resources.
Furthermore, it emphasised that the maternal health sector was at a critical juncture where technology could play a pivotal role in improving access and outcomes.
HMD said its latest funding round would help scale its solutions and create meaningful impact in communities where it’s needed most.
Managing director and CEO Anoushka Gungadin said HMD was committed to improving prenatal and postnatal care for women globally.
“This strategic investment marks a transformative moment in our journey,” she said.
“It provides us with additional capital to drive our growth and validates our commitment to delivering positive social impact in the healthcare sector.”
Gungadin said the global healthcare landscape faced mounting challenges in care accessibility, workforce shortages, and escalating costs, adding:
“HeraCARE continues to demonstrate its potential as a comprehensive solution to these pressing issues, with an expanding body of evidence supporting its efficacy.”
This article was developed in collaboration with HeraMED, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
